Portal de Periódicos da CAPES

Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies

2018; IOS Press; Volume: 62; Issue: 3 Linguagem: Inglês

10.3233/jad-171145

1875-8908

Ralph N. Martins, Victor L. Villemagne, Hamid R. Sohrabi, Pratishtha Chatterjee, Tejal Shah, Giuseppe Verdile, Paul E. Fraser, Kevin Taddei, Veer Bala Gupta, Stephanie R. Rainey‐Smith, Eugene Hone, Steve Pedrini, Wei Ling Florence Lim, Ian Martins, Shaun Frost, Sunil M. Gupta, Sid E. O’Bryant, Alan Rembach, David Ames, Kathryn A. Ellis, Stephanie Fuller, Belinda M. Brown, Samantha L. Gardener, Binosha Fernando, Prashant Bharadwaj, Samantha Burnham, Simon M. Laws, Anna M. Barron, Kathryn Goozee, Eka Julianta Wahjoepramono, Prita R. Asih, James D. Doecke, Olivier Salvado, Ashley I. Bush, Christopher C. Rowe, Sam Gandy, Colin L. Masters,

Nutritional Studies and Diet

Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050.The cost to the community and government health systems, as well as the stress on families and carers is incalculable.Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-␤ peptide (also known as A␤ or A4 peptide) extracted from cerebral amyloid plaques.This review discusses the journey from the discovery of the A␤ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye.The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years.AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E 4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral A␤.